Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus

Completed · Not applicable

Conditions studied: Hepatitis C

In brief

The purpose of this study is to determine whether treatment with Daclatasvir/Asunaprevir/BMS-791325, with or without ribavirin, for 8, 6, or 4 weeks is feasible for the treatment of genotype 1a chronic hepatitis C in patients without cirrhosis.

Key facts

Study ID

NCT02098616

Run by

Timothy Morgan, MD

People needed

25

Starts

2014-07-01

Expected to finish

2016-02-01

Last updated by the study team

2016-04-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects chronically infected with HCV genotype 1a
• HCV RNA ≥ 10,000 IU/mL at screening
• Treatment-naïve subjects with no previous exposure to an interferon formulation (ie, IFNα, pegIFNα), ribavirin (RBV), or HCV direct acting antiviral (DAA; protease, polymerase inhibitor, etc.)

You may not qualify if…

• Evidence of cirrhosis
• Liver or any other organ transplant
• Current or known history of cancer within 5 years prior to enrollment
• Documented or suspected hepatocellular carcinoma (HCC)
• Not eligible for sofosbuvir + pegylated interferon + ribavirin therapy

Where it is running

• VA Long Beach Healthcare System — Long Beach, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.